

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|

| | |
|-------------------------------|---------------|
| Application Number | |
| Filing Date | |
| First Named Inventor | David WALLACH |
| Group Art Unit | 1644 |
| Examiner Name | |
| Attorney Docket Number | WALLACH=10D |

[illegible][illegible]Date
Considered

* Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

PHUNG GINGER 5/29/07

| | | | | | |
|---|---|----|---|------------------------|-------------|
| Substitute for form 1449A/PTO | | | | Compleat if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor | |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 2 | of | 4 | Attorney Docket Number | WALLACH=10C |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | AL | BALAVOINE et al, "Prostaglandin E ₂ and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitor(s)", <u>J Clin Invest</u> 78:1120-1124 (1986) | |
| | AM | BEUTLER et al, "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", <u>Science</u> 229:869-871 (1985) | |
| | AN | BEUTLER et al, "Cachectin: More than a Tumor Necrosis Factor", <u>New Eng J Med</u> 316(7):379-385 (1987) | |
| | AO | BEUTLER et al, <u>Tumor Necrosis Factors ...</u> , Raven Press, New York, pp. 145, 383 (1992) | |
| | AP | BIGDA et al, "Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity", <u>J Exp Med</u> 180:445-460 (1994) | |
| | AQ | BROCKHAUS et al, "Monoclonal Antibodies against the TNF-Receptor Inhibit ...", 2 nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 140 | |
| | AR | BROCKHAUS et al, "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies", <u>Proc Natl Acad Sci U S A</u> 87(8):3127-3131 (1990) | |
| | AS | CHEN et al, "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", <u>J Biol Chem</u> 270(6):2874-2878 (1995) (Abstract) | |
| | AT | CREASEY et al, "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines", <u>Cancer Research</u> 47:145-149 (1987) | |
| | AU | ENGELMANN et al, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine", <u>J Biol Chem</u> 265(3):1531-1536 91990) | |
| | AV | HARRIS et al, "Therapeutic antibodies - the coming of age", <u>TIBTECH</u> 11:42-44 (1993) | |
| | AW | HIGUCHI et al, "Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies", <u>J Biol Chem</u> 267(29):20892-20899 (1992) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

Ther Gange 5/29/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---|------|------------------------|---------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | |
| | | Filing Date | |
| | | First Named Inventor | David WALLACH |
| | | Group Art Unit | 1644 |
| | | Examiner Name | |
| Sheet 3 | of 4 | Attorney Docket Number | WALLACH=10C |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | AX | HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", <u>J Biol Chem</u> 264(25):14927-14934 (1989) | |
| | AY | HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", 2 nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 143 | |
| | AZ | LOETSCHER et al, "Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells", <u>J Biol Chem</u> 265(33):20131-20138 (1990) | |
| | BA | NATANSON et al, "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", <u>Annals of Int Med</u> 120(9):771-783 (1994) | |
| | BB | PARRILLO JE, "Pathogenetic Mechanisms of Septic Shock", <u>New Eng J Med</u> 328(20):1471-1477 (1993) | |
| | BC | PEETRE et al, "A tumor necrosis factor binding protein is present in human biological fluids", <u>Eur J Haematol</u> 41:414-419 (1988) | |
| | BD | SCHALL et al, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", <u>Cell</u> 61:361-370 (1990) | |
| | BE | SECKINGER et al, "A Human Inhibitor of Tumor Necrosis Factor alpha", <u>J Exp Med</u> 167:1511-1516 (1988) | |
| | BF | SMITH et al, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", <u>Science</u> 248:1019-1023 (1990) | |
| | BG | STAUBER et al, "Human Tumor Necrosis Factor-alpha Receptor", <u>J Biol Chem</u> 263(35):19098-19104 (1986) | |
| | BH | TRACEY et al, "Shock and Tissue Injury Induced by Recombinant Human Cachectin", <u>Science</u> 234:470-474 (1986) | |
| | BI | TRACEY et al, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" <u>Nature</u> 330:662-664 (1987) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

Philip Gaudin 5/24/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---|------------------------|----------------------|---------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | |
| | | Filing Date | |
| | | First Named Inventor | David WALLACH |
| | | Group Art Unit | 1644 |
| | | Examiner Name | |
| Sheet 4 of 4 | Attorney Docket Number | WALLACH=10C | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | BJ | UNGLAUB et al, "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators", <u>J Exp Med</u> 166:1788-1797 (1987) | |
| | BK | WALLACH D, "Cytotoxins (Tumor Necrosis Factor, Lymphotoxin and Others); Molecular Functional Characteristics and interactions with interferons", <u>Interferon</u> 7:90-124 (1986) | |
| | BL | WEIR (Ed.), <u>Handbook of Experimental Immunology</u> , Vol. 1, Blackwell Scientific Publications; Oxford, pp. 8.14-8.15 | |
| | BM | WHITLOW et al, "Single-Chain Fv Proteins and Their Fusion Proteins", <u>Methods</u> 2(2):97-105 (1991) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

Patricia M. Jones 5/24/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---|------------------------|---------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10632929 |
| | Filing Date | | 2003-08-04 |
| | First Named Inventor | David WALLACH | |
| | Art Unit | 1644 | |
| | Examiner Name | P. Gambel | |
| | Attorney Docket Number | WALLACH10D | |

| | | |
|--|---|--------------------------|
| 1 | ENGELMANN, H., et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity", Journal of Biological Chemistry, 265:14497-1504 (1990) | <input type="checkbox"/> |
| 2 | ESPEVIK, T., et al., "Characterization of Binding and Biological Effects of Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor", J. Exp. Med., 171:415-426 (1990) | <input type="checkbox"/> |
| If you wish to add additional non-patent literature document citation information please click the Add button | | |
| EXAMINER SIGNATURE | | |
| Examiner Signature | | Date Considered |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |
| <small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small> | | |

P. Gambel
Stralo 7



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/632,929 |
| Filing Date | August 4, 2003 |
| First Named Inventor | David WALLACH et al |
| Group Art Unit | 1644 |
| Examiner Name | Phillip Gambel |
| Attorney Docket Number | WALLACH=10D |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|-----------------------|-------------|---|--------------------------------|--|---|----------------|
| | | Country Code ⁴ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | T ² |
|-----------------------|-------------|--|--|--|----------------|
| | | | | | |
| PC | BN | BANNER et al, "Crystal Structure of the Soluble Human 55 kd TNF Receptor-human TNF Beta Complex: Implications for TNF Receptor Activation", <u>Cell</u> 73(3):431-451 (1993) | | | |
| I | BO | JAATTELA M, "Biologic Activities and Mechanisms of Action of Tumor Necrosis Factor-alpha/cachectin", <u>Lab Invest</u> 64(6):724-742 (1991) | | | |
| I | BP | MARSTERS et al, "Identification of Cystein-rich Domains of the Type 1 Tumor Necrosis Factor Receptor Involved in Ligand Binding", <u>J Biol Chem</u> 267(9):5747-5750 (1992) | | | |
| M | BQ | ROTHER et al, "Tumor Necrosis Factor Receptors-structure and Function", <u>Immunol Res</u> 11(2):81-90 (1992) | | | |
| | | | | | |
| | | | | | |

Examiner
Signature

Date

Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.